UroGen Acquires Oncolytic Virus ICVB-1042, Announce Research Deals
20 Feb 2025 //
BUSINESSWIRE
IconOVir Bio Announces First Patient Dosed in Phase 1 Trial of ICVB-1042
11 Jul 2023 //
BUSINESSWIRE
IconOVir Bio to Present at Jefferies Healthcare Conference
31 May 2023 //
BUSINESSWIRE
IconOVir Bio to Present at Oppenheimer 33rd Annual Healthcare Conference
07 Mar 2023 //
BUSINESSWIRE
IconOVir Announces New Preclinical Data Showcasing of ICVB-1042
10 Nov 2022 //
BUSINESSWIRE